Publicação
Anticancer peptide SVS-1 : efficacy precedes membrane neutralization
| dc.contributor.author | Gaspar, Diana | |
| dc.contributor.author | Veiga, Ana Salomé | |
| dc.contributor.author | Sinthuvanich, Chomdao | |
| dc.contributor.author | Schneider, Joel P. | |
| dc.contributor.author | Castanho, Miguel A. R. B. | |
| dc.date.accessioned | 2012-11-15T12:37:52Z | |
| dc.date.available | 2012-11-15T12:37:52Z | |
| dc.date.issued | 2012 | |
| dc.description | © 2012 American Chemical Society - The final version of record is available at http://pubs.acs.org/journal/bichaw | eng |
| dc.description.abstract | Anticancer peptides are polycationic amphiphiles capable of preferentially killing a wide spectrum of cancer cells relative to noncancerous cells. Their primary mode of action is an interaction with the cell membrane and subsequent activation of lytic effects; however, the exact mechanism responsible for this mode of action remains controversial. Using zeta potential analyses we demonstrate the interaction of a small anticancer peptide with membrane model systems and cancer cells. Electrostatic interactions have a pivotal role in the cell killing process, and in contrast to the antimicrobial peptides action cell death occurs without achieving full neutralization of the membrane charge. | eng |
| dc.description.sponsorship | Partial Financial Support for this work was provided by FCT (Lisbon), through the contract PTDC/SAU-BEB/099142/2008. This work was also supported by the Intramural Research Program of the National Cancer Institute of the NIH. - D.G. acknowledges Fundação para a Ciência e a Tecnologia (Ministério da Educação e Ciência, Portugal) for Fellowship SFRH/BPD/73500/2010. A.S.V. acknowledges a Marie Curie International Outgoing Fellowship within the 7th European Community Framework Programme (PIOF-GA-2009-235154). C.S. acknowledges the Strategic Scholarship for Frontier Research Network (SFR) from Office of the Higher Education Commission, Ministry of Education, Thailand. | eng |
| dc.identifier.citation | Biochemistry 2012, 51, 6263−6265 | eng |
| dc.identifier.issn | 0006-2960 | |
| dc.identifier.uri | hhtp://dx.doi.org/10.1021/bi300836r | |
| dc.identifier.uri | http://hdl.handle.net/10451/7233 | |
| dc.language.iso | eng | por |
| dc.peerreviewed | yes | por |
| dc.publisher | American Chemical Society | eng |
| dc.title | Anticancer peptide SVS-1 : efficacy precedes membrane neutralization | eng |
| dc.type | journal article | |
| dspace.entity.type | Publication | |
| oaire.citation.endPage | 6265 | por |
| oaire.citation.startPage | 6263 | por |
| oaire.citation.title | Biochemistry | eng |
| rcaap.rights | restrictedAccess | por |
| rcaap.type | article | por |